A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder

This study has been completed.
Sponsor:
Collaborator:
Targacept Inc.
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01152554
First received: June 28, 2010
Last updated: March 14, 2014
Last verified: March 2014
Results First Received: June 26, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Conditions: Major Depressive Disorder
MDD
Depression
Interventions: Drug: TC-5214
Drug: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
This multicenter study was conducted in the US between 22 June 2010 and 07 February 2012.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
The study had an up to 21-day screening/washout period, and an 6-week prospective open-label antidepressant treatment (ADT) period to identify the target patient population of inadequate responders to ADT (a HAMD-17 total score of ≥10 and a CGI-S score ≥3).

Reporting Groups
  Description
TC-5214 Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 1-4 mg BID
Placebo Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + Placebo BID

Participant Flow:   Overall Study
    TC-5214     Placebo  
STARTED     610     203  
Received Treatment     607     201  
COMPLETED     276     92  
NOT COMPLETED     334     111  
Withdrawal by Subject                 73                 28  
Eligiblity criteria not fulfilled                 0                 1  
Adverse Event                 67                 14  
Severe non-compliance to protocol                 36                 14  
Condition under investigation worsened                 5                 2  
Lack of Efficacy                 20                 3  
Study-specific withdrawal criteria                 17                 8  
Lost to Follow-up                 87                 32  
Not specified                 28                 8  
Death                 1                 1  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
TC-5214 Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 1-4 mg BID
Placebo Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + Placebo BID
Total Total of all reporting groups

Baseline Measures
    TC-5214     Placebo     Total  
Number of Participants  
[units: participants]
  610     203     813  
Age  
[units: years]
Mean ± Standard Deviation
  43.2  ± 11.68     42.8  ± 11.75     43.1  ± 11.69  
Gender  
[units: participants]
     
Female     418     148     566  
Male     192     55     247  
Race/Ethnicity, Customized  
[units: participants]
     
White     467     149     616  
Black or African American     121     44     165  
Asian     10     4     14  
Native Hawaiian or other Pacific Islander     1     0     1  
American Indian or Alaska Native     0     2     2  
Other     11     4     15  
Hamilton Rating Scale for Depression-17 items (HAMD-17) total score at randomization [1]
[units: Scores on a scale]
Mean ± Standard Deviation
  18.4  ± 4.49     18.6  ± 4.61     18.5  ± 4.52  
Montgomery-Asberg Depression Rating Scale (MADRS) total score at randomization [2]
[units: Scores on a scale]
Mean ± Standard Deviation
  23.5  ± 6.34     23.4  ± 5.85     23.4  ± 6.21  
[1] A 17-item, clinician-rated scale that assesses depressive symptoms. The HAMD-17 consists of 17 symptoms, each of which is rated from 0 to 2 or 0 to 4, where 0 is none/absent. The HAMD-17 total score is calculated as the sum of the 17 individual symptom scores; the total score can range from 0 to 52. Higher HAMD-17 scores indicate more severe depression.
[2] A 10-item scale for the evaluation of depressive symptoms. Each MADRS item is rated on a 0 to 6 scale. The MADRS total score is calculated as the sum of the 10 individual item scores; the total score can range from 0 to 60. Higher MADRS scores indicate higher levels of depressive symptoms.



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Frequency of Patients Experiencing at Least One Adverse Event (AE)   [ Time Frame: Randomization (Week 0) to end of the follow-up period (Week 54) ]

2.  Primary:   Frequency of Patients Experiencing AEs That Resulted in Discontinuation of Investigational Product (IP)   [ Time Frame: Randomization (Week 0) to end of the follow-up period (Week 54) ]

3.  Primary:   Frequency of Patients Experiencing Serious Adverse Events (SAEs)   [ Time Frame: Randomization (Week 0) to end of the follow-up period (Week 54) ]

4.  Secondary:   Sustained Efficacy at 3 Months, Defined as a Montgomery-Asberg Depression Rating Scale (MADRS) Total Score of ≤12 at Week 12 and All Visits up to and Including Week 24   [ Time Frame: Week 12 to Week 24 ]

5.  Secondary:   Sustained Efficacy at 9 Months, Defined as a MADRS Total Score of ≤12 at Week 12 and at All Visits up to and Including Week 52   [ Time Frame: Week 12 to Week 52 ]

6.  Secondary:   Change in the Clinician-rated Global Outcome of Severity as Measured by the Clinical Global Impression-Severity (CGI-S) Score From Randomization (Week 0) to End of Treatment (Week 52)   [ Time Frame: Randomization (Week 0) to end of treatment (Week 52) ]

7.  Secondary:   Change in Functional Impairment From Randomization (Week 0) to End of Treatment (Week 52) as Measured by the Sheehan Disability Scale (SDS) Total Score   [ Time Frame: Randomization (Week 0) to end of treatment (Week 52) ]

8.  Secondary:   Change in Overall Quality of Life and Satisfaction From Randomization (Week 0) to End of Treatment (Week 52) by Assessing the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) % Maximum Total Score   [ Time Frame: Randomization (Week 0) to end of treatment (Week 52) ]

9.  Secondary:   Change in EuroQol - 5 Dimensions (EQ-5D) From Randomization (Week 0) to End of Treatment (Week 52)   [ Time Frame: Randomization (Week 0) to end of treatment (Week 52) ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Gerard Lynch
Organization: AstraZeneca
e-mail: aztrial_results_posting@astrazeneca.com


No publications provided


Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01152554     History of Changes
Other Study ID Numbers: D4130C00007
Study First Received: June 28, 2010
Results First Received: June 26, 2012
Last Updated: March 14, 2014
Health Authority: United States: Food and Drug Administration